Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HBB | P68871 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | HPRT1 | P00492 | 15/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | PNP | P00491 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | EDNRA | P25101 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL713052 | 1.00 | MEN1 (0.51) | MEN1KMT2AHBBMAPK1PDE3A | |
| SCHEMBL710683 | 1.00 | MEN1 (0.51) | MEN1KMT2AHBBMAPK1PDE3A | |
| SCHEMBL709457 | 1.00 | MEN1 (0.51) | MEN1KMT2AHBBMAPK1PDE3A | |
| SCHEMBL710794 | 1.00 | MEN1 (0.51) | MEN1KMT2AHBBMAPK1PDE3A | |
| SCHEMBL709456 | 1.00 | MEN1 (0.51) | MEN1KMT2AHBBMAPK1PDE3A | |
| SCHEMBL709971 | 1.00 | MEN1 (0.51) | MEN1KMT2AHBBMAPK1PDE3A | |
| SCHEMBL713054 | 1.00 | MEN1 (0.51) | MEN1KMT2AHBBMAPK1PDE3A | |
| SCHEMBL710684 | 1.00 | MEN1 (0.51) | MEN1KMT2AHBBMAPK1PDE3A | |
| SCHEMBL710793 | 1.00 | MEN1 (0.51) | MEN1KMT2AHBBMAPK1PDE3A | |
| SCHEMBL711664 | 1.00 | MEN1 (0.51) | MEN1KMT2AHBBMAPK1PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014047562-A2 | METHOD OF TREATING AND/OR PREVENTING SHINGLES AND METHOD OF TREATING AND/OR PREVENTING ZOSTER ASSOCIATED PAIN | EPIPHANY BIOSCIENCES (US) | 2014-03-27 | — | — | WO | disclosed |
| US-20120123119-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2012-05-17 | — | — | US | disclosed |
| US-8124609-B2 | Acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2012-02-28 | — | — | US | disclosed |
| WO-2011022712-A1 | METHOD OF TREATING INFECTIOUS MONONUCLEOSIS WITH ACYLIC NUCLEOSIDE DERIVATIVES | EPIPHANY BIOSCIENCES, INC. (US) | 2011-02-24 | — | — | WO | disclosed |
| US-20090076041-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2009-03-19 | — | — | US | disclosed |
| US-7432274-B2 | Acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2008-10-07 | — | — | US | disclosed |
| US-7189849-B2 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2007-03-13 | — | — | US | disclosed |
| US-20050250795-A1 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2005-11-10 | — | — | US | disclosed |
| US-6878844-B2 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2005-04-12 | — | — | US | disclosed |
| US-20040248910-A1 | Synthesis of acyclic nucleoside derivatives | MEDIVIR AB (SE) | 2004-12-09 | — | — | US | disclosed |
| EP-0888348-B1 | ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2003-01-22 | — | — | EP | disclosed |
| US-20020188125-A1 | Acyclic nucleoside derivatives | MEDIVIR AB | 2002-12-12 | — | — | US | disclosed |
| US-6255312-B1 | VIRICIDES | MEDIVIR AB (SE) | 2001-07-03 | — | — | US | disclosed |
| US-6184376-B1 | POTENT ANTIVIRALS, ESPECIALLY AGAINST HERPES INFECTIONS, SUCH AS THOSE CAUSED BY VARICELLA ZOSTER VIRUS, HERPES SIMPLEX, EPSTEIN-BARR VIRUS, HERPES TYPE 6 (HHV-6) AND TYPE 8 (HHV-8). SHINGLES IN THE ELDERLY OR CHICKEN POX IN THE YOUNG | MEDIVER AB (SE) | 2001-02-06 | — | — | US | disclosed |
| EP-0971923-A2 | SYNTHESIS OF ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 2000-01-19 | — | — | EP | disclosed |
| EP-0888348-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | Medivir Aktiebolag (SE) | 1999-01-07 | — | — | EP | disclosed |
| EP-0880521-A1 | SYNTHESIS OF ACYCLIC NUCLEOSIDES | Medivir Aktiebolag (SE) | 1998-12-02 | — | — | EP | disclosed |
| WO-1998034917-A2 | SYNTHESIS OF ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 1998-08-13 | — | — | WO | disclosed |
| WO-1997030051-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | MEDIVIR AB (SE) | 1997-08-21 | — | — | WO | disclosed |
| WO-1997030052-A1 | SYNTHESIS OF ACYCLIC NUCLEOSIDES | MEDIVIR AB (SE) | 1997-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076041-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | NUDT1, PNP, NSUN2 | MEN1 1917/4885KMT2A 2396/4885HBB 1470/4885 |
| US-20120123119-A1 | ACYCLIC NUCLEOSIDE DERIVATIVES | NUDT1, PNP, NSUN2 | MEN1 1895/4885KMT2A 2400/4885HBB 1507/4885 |
| US-20040248910-A1 | Synthesis of acyclic nucleoside derivatives | NSUN2, SLC28A1, NUDT1 | MEN1 1883/4885KMT2A 2577/4885HBB 2205/4885 |
| US-20050250795-A1 | Synthesis of acyclic nucleoside derivatives | ASNS, NUDT1, PNP | MEN1 1376/4885KMT2A 2608/4885HBB 2182/4885 |
| US-20020188125-A1 | Acyclic nucleoside derivatives | NSUN2, NUDT1, PNP | MEN1 2510/4885KMT2A 2354/4885HBB 1623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.